Imagerolan (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of downstream signaling proteins, it stops the uncontrolled proliferation of malignant cells that depend on these pathways, leading to tumor regression or disease stabilization.

The exact dose of Imagerolan is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. No standard dosing can be provided without a medical assessment.

Imagerolan’s pregnancy category is unknown, and animal studies suggest potential risk to the fetus. It is generally advised to avoid use during pregnancy and lactation unless the potential benefit outweighs the risk. Patients should discuss alternatives with their healthcare provider.

To request Imagerolan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Imagerolan (imatinib) is the first‑generation BCR‑ABL inhibitor and is often compared with newer agents such as dasatinib or nilotinib. While newer TKIs may offer faster molecular responses, imatinib remains a well‑studied, cost‑effective option with a long safety record for the approved indications.

Imagerolan should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep the container tightly closed when not in use.

Imagerolan is taken orally as a tablet, usually with a glass of water. It may be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and whether to swallow whole or split the tablet.

The most serious adverse events include hepatotoxicity (elevated liver enzymes or hepatitis), severe myelosuppression (low blood counts leading to infection or bleeding), and cardiac toxicity such as congestive heart failure or QT‑interval prolongation. Prompt medical attention is required if any of these occur.

Imagerolan is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those receiving interacting medications that cannot be managed.